Companies › Gilead Sciences
49 active drug programs in 209 registered trials: 104 Phase 2, 49 Phase 1, 37 Phase 3, 19 Phase 4; Oncology, Infectious disease, Neurology, Immunology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Cobicistat Cytochrome P450 3A inhibitor | CYP3A4, CYP3A5, CYP3A43, CYP3A7 | Phase 4 | HIV-1-infection; AML, Adult | Jun 2027 |
| F/TAF (High Dose Tablet) Nucleoside reverse transcriptase inhibitor (NRTI) combination: emtricitabine + tenofovir a | – | Phase 4 | HIV-1-infection | Jun 2027 |
| Sacituzumab Govitecan Tumor-associated calcium signal transducer 2 binding agent; DNA topoisomerase I inhibitor | TACSTD2, TOP1 | Phase 3 | Metastatic Breast Cancer; Non-Small Cell Lung Cancer; Triple Negative Breast Cancer; Locally Advanced or Unresectable Metastatic Breast Cancer … | Dec 2026 |
| Zimberelimab Programmed cell death protein 1 inhibitor | PDCD1 | Phase 3 | Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer … | Dec 2026 |
| Domvanalimab T-cell immunoreceptor with Ig and ITIM domains inhibitor | TIGIT | Phase 3 | Non-small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma; Advanced Non-Small Cell Lung Cancer; Lung Cancer … | Mar 2027 |
| Lenacapavir Structural capsid protein inhibitor | CA, CPSF6, GAG, PROT, UNKNOWN, CAPSID | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection … | Mar 2027 |
| Bictegravir Human immunodeficiency virus type 1 integrase inhibitor | INTEGRASE, ABCC10 | Phase 3 | HIV-1-infection; HIV-1 Infection; HIV -1 Infection; HIV Infections | Jun 2027 |
| Tenofovir Disoproxil Fumarate Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLA1, POLB | Phase 3 | Chronic Hepatitis B; Hepatitis B; Hepatitis B Infection; Parkinson Disease | Jul 2027 |
| Emtricitabine Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLR2A, POLR1C | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection; Hiv; Alcohol Use, Unspecified; Pre-exposure Prophylaxis … | Jan 2028 |
| Islatravir Reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor | RT, IN, POLB, INTS1, INTS8 | Phase 3 | HIV-1-Infection; HIV-1-infection; HIV-1 Infection | Mar 2028 |
| anitocabtagene autoleucel BCMA-directed CAR-T cell therapy | BCMA | Phase 3 | Multiple Myeloma; Muscular Diseases | Jul 2028 |
| Seladelpar Peroxisome proliferator-activated receptor delta agonist | PPARD | Phase 3 | Primary Biliary Cirrhosis; Primary Biliary Cholangitis | Nov 2028 |
| Teropavimab Anti-gp120 monoclonal antibody | ENV | Phase 3 | HIV Infections; HIV-1-infection; HIV-1 Infection | Mar 2029 |
| Zinlirvimab Envelope protein inhibitor | ENV | Phase 3 | HIV Infections; HIV-1-infection; HIV-1 Infection; HIV/AIDS and Infections … | Mar 2029 |
| KITE-753 Anti-CD19 CAR-T cell therapy | CD19 | Phase 3 | Relapsed or Refractory Large B-cell Lymphoma; Relapsed and/or Refractory B-cell Lymphoma | Feb 2030 |
| Axicabtagene Ciloleucel B-lymphocyte antigen CD19 binding agent | CD19 | Phase 3 | Relapsed/Refractory Follicular Lymphoma; High-risk Large B-cell Lymphoma (LBCL); Lymphoma, B-Cell; B-Cell Lymphoma Refractory … | Oct 2030 |
| anitocabtagene-autoleucel | – | Phase 2 | Multiple Myeloma; Relapsed and Refractory Multiple Myeloma | Dec 2026 |
| Tilpisertib Mitogen-activated protein kinase kinase kinase 8 inhibitor | MAP3K8 | Phase 2 | Ulcerative Colitis | Jan 2027 |
| ATV/co HIV protease inhibitor boosted by cobicistat | PROTEASE | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS) | Mar 2027 |
| DRV/co HIV protease inhibitor boosted by cobicistat | PROTEASE | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS) | Mar 2027 |
| Tenofovir Alafenamide Human immunodeficiency virus type 1 reverse transcriptase inhibitor | POLRMT, RT | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS); Chronic Hepatitis B; Hepatitis B Reactivation; Chronic Hepatitis b … | Mar 2027 |
| Brexucabtagene Autoleucel (X19) B-lymphocyte antigen CD19 binding agent | CD19 | Phase 2 | Relapsed/Refractory Mantle Cell Lymphoma; Mantle Cell Lymphoma; B-Cell Lymphoblastic Leukemia; Recurrent Mantle Cell Lymphoma … | Jul 2027 |
| GS-3242 HIV maturation inhibitor | – | Phase 2 | HIV-1-infection; HIV-1 Infection | Aug 2027 |
| Quemliclustat CD73 inhibitor | – | Phase 2 | Advanced Non-Small Cell Lung Cancer | Dec 2027 |
| Lepetegravir Integrase strand transfer inhibitor (INSTI) | INTEGRASE | Phase 2 | HIV-1-Infection | Jan 2028 |
| ISL/LEN FDC Fixed-dose combination of nucleotide reverse transcriptase translocation inhibitor and HIV | POLB, GAG | Phase 2 | HIV-1 Infection | Mar 2028 |
| emvistegrast (GS-1427) α4 integrin antagonist | ITGA4 | Phase 2 | Ulcerative Colitis | Apr 2028 |
| Cilofexor Bile acid receptor FXR agonist | NR1H4 | Phase 2 | Primary Biliary Cholangitis | Dec 2028 |
| Denikitug (GS-1811) | – | Phase 2 | Advanced Microsatellite Stable Colorectal Cancer; HER2-negative; Advanced Solid Tumor | Dec 2028 |
| Etrumadenant Adenosine A2a receptor antagonist; Adenosine A2b receptor antagonist | ADORA2A, ADORA2B | Phase 2 | Lung Cancer; Oligometastatic Prostate Cancer; Rectal Cancer; Pancreatic Ductal Adenocarcinoma … | Sep 2029 |
| BIC/LEN FDC Combination of integrase strand transfer inhibitor and capsid inhibitor | INSR, POLLEN | Phase 2 | HIV-1-infection | Dec 2029 |
| KITE-197 CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Relapsed/Refractory Large B-cell Lymphoma | Nov 2026 |
| GS-9911 | – | Phase 1 | Solid Tumors | Dec 2026 |
| GS-4571 | – | Phase 1 | Weight Management | Feb 2027 |
| GS-0151 | – | Phase 1 | Rheumatoid Arthritis | Mar 2027 |
| TUB-040 NaPi2b antibody-drug conjugate (ADC) | SLC34A2 | Phase 1 | Ovarian Cancer | Dec 2027 |
| GS-5319 MTAP inhibitor | MTAP | Phase 1 | Advanced Solid Tumor | May 2028 |
| GS-2121 | – | Phase 1 | Advanced Solid Tumors | Jun 2028 |
| GS-0201 | – | Phase 1 | Advanced Solid Tumors | Sep 2028 |
| TUB-030 | – | Phase 1 | Advanced Solid Tumors | Dec 2028 |
| GS-2426 MTAP inhibitor | MTAP | Phase 1 | Advanced Solid Tumors | Jan 2029 |
| KITE-363 CAR-T cell therapy targeting CD19 | CD19 | Phase 1 | Chronic Inflammatory Demyelinating Polyneuropathy; Relapsed and/or Refractory B-cell Lymphoma | Jun 2029 |
| GS-0415 unclear - mechanism not stated in registry | – | Phase 1 | HIV -1 Infection | Aug 2029 |
| GS-1206 | – | Phase 1 | Solid Tumor | Sep 2029 |
| GS-4321 | – | Phase 1 | Chronic Hepatitis Delta | Jan 2030 |
| ARC-T Cells Autologous T cells with chimeric antigen receptor (CAR) binding to CD123 via soluble prote | – | Phase 1 | Acute Myeloid Leukemia | – |
| GS-4528 | – | Phase 1 | Solid Tumor | – |
| INT2104 CD20-targeting CAR (chimeric antigen receptor) delivered by lentiviral vector | CD20 | Phase 1 | Lymphomas Non-Hodgkin's B-Cell | – |
| SPRX002 Soluble protein antigen-receptor X-linker with CD123-targeting binding region; serves as b | CD123 | Phase 1 | Acute Myeloid Leukemia | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT03489239 | Tenofovir Alafenamide | Phase 3 | Hepatitis B | Infectious disease | Aug 2020 |
| NCT04531046 | Axicabtagene Ciloleucel | Phase 2 | B-Cell Lymphoma Refractory | Oncology | Apr 2022 |
| NCT03343431 | Tenofovir Disoproxil Fumarate | Phase 3 | Hepatitis B | Infectious disease | May 2023 |
| NCT04616963 | Emtricitabine | Phase 4 | Hiv | Infectious disease | Jan 2024 |
| NCT05824468 | Zimberelimab | Phase 2 | Cervical Cancer | Oncology | Jul 2024 |
| NCT04619082 | Tenofovir Alafenamide | Phase 4 | Hepatitis B Reactivation | Infectious disease | Dec 2024 |
| NCT05853718 | Tenofovir Alafenamide | Phase 4 | Chronic Hepatitis b | Infectious disease | Dec 2025 |
| NCT06356662 | Tenofovir Disoproxil Fumarate | Phase 1 | Parkinson Disease | Neurology | Dec 2025 |
| NCT04331704 | Emtricitabine | Phase 4 | Alcohol Use, Unspecified | Psychiatry | Dec 2025 |
| NCT07210528 | Emtricitabine | Phase 1 | Mild Cognitive Impairment (MCI) | Neurology | Sep 2026 |
| NCT05119907 | Sacituzumab Govitecan | Phase 2 | Solid Tumor | Oncology | Oct 2026 |
| NCT05840224 | Zimberelimab | Phase 1 | Solid Tumor | Oncology | Oct 2026 |
| NCT05457010 | ARC-T Cells | Phase 1 | Acute Myeloid Leukemia | Oncology | Oct 2026 |
| NCT05457010 | SPRX002 | Phase 1 | Acute Myeloid Leukemia | Oncology | Oct 2026 |
| NCT05840224 | GS-4528 | Phase 1 | Solid Tumor | Oncology | Oct 2026 |
| NCT06539338 | INT2104 | Phase 1 | Lymphomas Non-Hodgkin's B-Cell | Oncology | Oct 2026 |
| NCT06511063 | Emtricitabine | Phase 2 | Long Covid | Infectious disease | Nov 2026 |
| NCT06079164 | KITE-197 | Phase 1 | Relapsed/Refractory Large B-cell Lymphoma | Oncology | Nov 2026 |
| NCT05915442 | Zimberelimab | Phase 2 | Oligometastatic Prostate Cancer | Oncology | Dec 2026 |
| NCT05688215 | Zimberelimab | Phase 1 | Borderline Resectable Pancreatic Adenocarcinoma | Oncology | Dec 2026 |
| NCT05915442 | Etrumadenant | Phase 2 | Oligometastatic Prostate Cancer | Oncology | Dec 2026 |
| NCT05300035 | Zinlirvimab | Phase 2 | HIV/AIDS and Infections | Infectious disease | Dec 2026 |
| NCT04639986 | Sacituzumab Govitecan | Phase 3 | Metastatic Breast Cancer | Oncology | Dec 2026 |
| NCT03964727 | Sacituzumab Govitecan | Phase 2 | Metastatic Solid Tumor | Oncology | Dec 2026 |
| NCT04617522 | Sacituzumab Govitecan | Phase 1 | Advanced or Metastatic Solid Tumor | Oncology | Dec 2026 |
| NCT06104592 | Axicabtagene Ciloleucel | Phase 2 | Large B-cell Lymphoma | Oncology | Dec 2026 |
| NCT05396885 | anitocabtagene-autoleucel | Phase 2 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT06082960 | Zimberelimab | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT05024097 | Zimberelimab | Phase 2 | Rectal Cancer | Oncology | Dec 2026 |
| NCT06048133 | Zimberelimab | Phase 2 | Biliary Tract Carcinoma | Oncology | Dec 2026 |
| NCT05024097 | Etrumadenant | Phase 2 | Rectal Cancer | Oncology | Dec 2026 |
| NCT06082960 | GS-9911 | Phase 1 | Solid Tumors | Oncology | Dec 2026 |
| NCT06158126 | Emtricitabine | Phase 4 | Pre-exposure Prophylaxis | Infectious disease | Dec 2026 |
| NCT06055738 | Zimberelimab | Phase 2 | Locally Advanced Cervical Cancer | Oncology | Dec 2026 |
| NCT04340596 | Zinlirvimab | Phase 1 | HIV Infection | Infectious disease | Dec 2026 |
| NCT06826118 | Axicabtagene Ciloleucel | Phase 2 | Lymphoma | Oncology | Dec 2026 |
| NCT04496882 | Tenofovir Alafenamide | Phase 4 | Chronic Hepatitis b | Infectious disease | Dec 2026 |
| NCT04704024 | Tenofovir Disoproxil Fumarate | Phase 3 | Hepatitis B Infection | Infectious disease | Dec 2026 |
| NCT07349758 | Emtricitabine | Phase 1 | Healthy Volunteer | Infectious disease | Jan 2027 |
| NCT05089734 | Sacituzumab Govitecan | Phase 3 | Non-Small Cell Lung Cancer | Oncology | Jan 2027 |
| NCT06029972 | Tilpisertib | Phase 2 | Ulcerative Colitis | Immunology | Jan 2027 |
| NCT04780204 | Tenofovir Alafenamide | Phase 4 | Hepatitis B, Chronic | Infectious disease | Jan 2027 |
| NCT07254754 | Axicabtagene Ciloleucel | Phase 2 | DIFFUSE LARGE B-CELL LYMPHOMA | Oncology | Jan 2027 |
| NCT05382286 | Sacituzumab Govitecan | Phase 3 | Triple Negative Breast Cancer | Oncology | Feb 2027 |
| NCT06238921 | Zimberelimab | Phase 1 | Breast Cancer | Oncology | Feb 2027 |
| NCT06562907 | GS-4571 | Phase 1 | Weight Management | Metabolic and endocrine | Feb 2027 |
| NCT05186974 | Sacituzumab Govitecan | Phase 2 | Non-small Cell Lung Cancer | Oncology | Mar 2027 |
| NCT06727565 | Zimberelimab | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Mar 2027 |
| NCT07424664 | Zimberelimab | Phase 2 | Uterine Cervical Neoplasms, Recurrent; Uterine Cervical Neoplasms, Metastatic; Vulvar Neoplasms; Vaginal Neoplasms | Oncology | Mar 2027 |
| NCT06727565 | Domvanalimab | Phase 2 | Head and Neck Squamous Cell Carcinoma | Oncology | Mar 2027 |
| NCT06749054 | Lenacapavir | Phase 2 | HIV-1-infection | Infectious disease | Mar 2027 |
| NCT06749054 | Lenacapavir | Phase 2 | HIV-1-infection | Infectious disease | Mar 2027 |
| NCT02016924 | Tenofovir Alafenamide | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS) | Infectious disease | Mar 2027 |
| NCT02016924 | ATV/co | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS) | Infectious disease | Mar 2027 |
| NCT02016924 | DRV/co | Phase 2 | Acquired Immune Deficiency Syndrome (AIDS) | Infectious disease | Mar 2027 |
| NCT06902519 | GS-0151 | Phase 1 | Rheumatoid Arthritis | Immunology | Mar 2027 |
| NCT07210125 | Lenacapavir | Phase 4 | HIV | Infectious disease | Mar 2027 |
| NCT05612178 | Zinlirvimab | Phase 1 | HIV-1 | Infectious disease | Mar 2027 |
| NCT06048484 | Zimberelimab | Phase 2 | Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2027 |
| NCT06048484 | Etrumadenant | Phase 2 | Pancreatic Ductal Adenocarcinoma | Oncology | Apr 2027 |
The 60 nearest readouts of 209 trials; the rest in the app.
Cash and short-term investments of $6.4bn on 2026-09-30; operating cash flow positive
Press releases filed as 8-K in the last year:
Held by 6 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.